The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Strategies to Tackle the Global Burden of Diabetic Retinopathy: From Epidemiology to Artificial Intelligence
Abstract
Diabetes is a global public health disease projected to affect 642 million adults by 2040, with about 75% residing in low- and middle-income countries. Diabetic retinopathy (DR) affects 1 in 3 people with diabetes and remains the leading cause of blindness in working-aged adults. There are 3 broad strategic imperatives to prevent blindness caused by DR. Primary prevention requires preventing or delaying the onset of DR in those with diabetes by systems-level lifestyle modifications such as increasing physical activity or dietary modifications, pharmacological interventions for glycaemic and blood pressure control, and systematic screening for the onset of DR. Secondary prevention requires preventing the progression of DR in patients with DR by continuing systemic risk factor control, regular screening to monitor for the progression of mild DR to vision-threatening stages, and the development and implementation of evidence-based guidelines for managing DR. In this aspect, telemedicine-based DR screening incorporating artificial intelligence technology has the potential to facilitate more widespread and cost-effective screening, particularly in low- and middle-income countries. Tertiary prevention of DR blindness has been the main focus of the clinical ophthalmology community, classically based on laser photocoagulation treatment and ocular surgery but with an increasing use of anti-vascular endothelial growth factor (anti-VEGF) for vision-threatening DR. Evidence from serial epidemiological studies shows blindness due to DR has declined in high-income countries (e.g., the USA and UK) due to coordinated public health education efforts, increased awareness, early detection by DR screening, sustained systemic risk factor control, and the availability of effective tertiary level treatment. However, the progress made in reducing DR blindness in high-income countries may be overwhelmed by the increasing numbers of patients with diabetes and DR in low- and middle-income countries (e.g., China, India, Indonesia, etc.). Thus, to tackle DR at a global level, a paradigm shift in strategic focus from tertiary towards secondary and primary prevention measures with a multi-pronged whole-of-society approach at regional and national levels is urgently needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gulshan, V., Peng, L., Coram, M., Stumpe, M. C., Wu, D., Narayanaswamy, A., Venugopalan, S., Widner, K., Madams, T., Cuadros, J., et al. (2016) · JAMA · doi:10.1001/jama.2016.17216 · Cited by 7,697
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
Ogurtsova, K., da Rocha Fernandes, J. D., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H., Cavan, D., Shaw, J. E., & Makaroff, L. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.024 · Cited by 6,966
Global prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985
Self-citationPrevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031
Ting, D. S. W., Cheung, C. Y.-L., Lim, G., Tan, G. S. W., Quang, N. D., Gan, A., Hamzah, H., Garcia-Franco, R., San Yeo, I. Y., Lee, S. Y., et al. (2017) · JAMA · doi:10.1001/jama.2017.18152 · Cited by 2,402
Self-citationEpidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
Lee, R., Wong, T. Y., & Sabanayagam, C. (2015) · Eye and Vision · doi:10.1186/s40662-015-0026-2 · Cited by 1,569
Self-citationPrevalence of Diabetic Retinopathy in the United States, 2005-2008
Zhang, X., Saaddine, J. B., Chou, C.-F., Cotch, M. F., Cheng, Y. J., Geiss, L. S., Gregg, E. W., Albright, A. L., Klein, B. E. K., & Klein, R. (2010) · JAMA · doi:10.1001/jama.2010.1111 · Cited by 1,196 · cited 1×
“In the USA, African-Americans and Mexicans are reported to have a higher prevalence of DR as well as VTDR than whites [24], attributed to poorer glycaemic control and lower screening and treatment rates in these minority ethnic groups.”
BackgroundAbràmoff, M. D., Lou, Y., Erginay, A., Clarida, W., Amelon, R., Folk, J. C., & Niemeijer, M. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-19964 · Cited by 1,101
Stratton, I. M., Kohner, E. M., Aldington, S. J., Turner, R. C., Holman, R. R., Manley, S. E., & Matthews, D. R. (2001) · Diabetologia · doi:10.1007/s001250051594 · Cited by 1,019 · cited 1×
“Similarly, hypertension and higher systolic blood pressure are important risk factors for DR, again demonstrated in many studies including prospective studies on type 1 [30] and type 2 [19, 31, 32] diabetes.”
Background
Cited by
Screening for diabetic retinopathy: new perspectives and challenges
Vujosevic, S., Aldington, S. J., Silva, P., Hernández, C., Scanlon, P., Peto, T., & Simó, R. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30411-5 · Cited by 671
Kropp, M., Golubnitschaja, O., Mazurakova, A., Koklesova, L., Sargheini, N., Vo, T.-T. K. S., de Clerck, E., Polivka, J., Potuznik, P., Polivka, J., et al. (2023) · EPMA Journal · doi:10.1007/s13167-023-00314-8 · Cited by 468
Integrated image-based deep learning and language models for primary diabetes care
Li, J., Guan, Z., Wang, J., Cheung, C. Y., Zheng, Y., Lim, L.-L., Lim, C. C., Ruamviboonsuk, P., Raman, R., Corsino, L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03139-8 · Cited by 250
Self-citationZhao, L., Wu, X., & Luo, H. (2022) · Sustainability · doi:10.3390/su142114549 · Cited by 239
Research integrity in the era of artificial intelligence: Challenges and responses
Chen, Z., Chen, C., Yang, G., He, X., Chi, X., Zeng, Z., & Chen, X. (2024) · Medicine · doi:10.1097/md.0000000000038811 · Cited by 109
Raman, R., Vasconcelos, J. C., Rajalakshmi, R., Prevost, A. T., Ramasamy, K., Mohan, V., Mohan, D., Rani, P. K., Conroy, D., Das, T., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00411-9 · Cited by 106
Cost-effectiveness of artificial intelligence screening for diabetic retinopathy in rural China
Huang, X.-M., Yang, B.-F., Zheng, W.-L., Liu, Q., Xiao, F., Ouyang, P.-W., Li, M.-J., Li, X.-Y., Meng, J., Zhang, T.-T., et al. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-07655-6 · Cited by 89
Mathenge, W., Whitestone, N., Nkurikiye, J., Patnaik, J. L., Piyasena, P., Uwaliraye, P., Lanouette, G., Kahook, M. Y., Cherwek, D. H., Congdon, N., et al. (2022) · Ophthalmology Science · doi:10.1016/j.xops.2022.100168 · Cited by 80
Teo, Z. L., Tham, Y.-C., Yu, M., Cheng, C.-Y., Wong, T. Y., & Sabanayagam, C. (2020) · Eye · doi:10.1038/s41433-020-0776-5 · Cited by 62
“Measures to prevent blindness from DR include effective primary and secondary prevention such as early detection by screening, effective DM management and compliance to recommended DR guidelines [20].”
BackgroundFonda, S. J., Bursell, S.-E., Lewis, D. G., Clary, D., Shahon, D., & Horton, M. B. (2020) · Telemedicine and e-Health · doi:10.1089/tmj.2019.0281 · Cited by 34
Benhamza, M., Dahlui, M., & Said, M. A. (2024) · BMC Ophthalmology · doi:10.1186/s12886-024-03665-6 · Cited by 32
He, F., Ng Yin Ling, C., Nusinovici, S., Cheng, C.-Y., Wong, T. Y., Li, J., & Sabanayagam, C. (2024) · Journal of Medical Internet Research · doi:10.2196/41065 · Cited by 29
Self-citationWang, Z., Li, Z., Li, K., Mu, S., Zhou, X., & Di, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1197783 · Cited by 27
Li, H., Li, G., Li, N., Liu, C., Yuan, Z., Gao, Q., Hao, S., Fan, S., & Yang, J. (2023) · PLOS ONE · doi:10.1371/journal.pone.0291390 · Cited by 27
Zhu, X., Xu, Y., Lu, L., & Zou, H. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000970 · Cited by 26
Chotcomwongse, P., Ruamviboonsuk, P., Karavapitayakul, C., Thongthong, K., Amornpetchsathaporn, A., Chainakul, M., Triprachanath, M., Lerdpanyawattananukul, E., Arjkongharn, N., Ruamviboonsuk, V., et al. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-024-01086-8 · Cited by 9
Economic Aspects in the Management of Diabetic Macular Edema in Italy
Calabrò, G. E., Basile, M., Varano, M., Amore, F., Ricciardi, R., Bandello, F., & Cicchetti, A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.938987 · Cited by 4
Chauhan, A., Goyal, A., Masih, R., Kaur, G., Kumar, L., Neha, ., Rastogi, H., Kumar, S., Singh, B. L., Syal, P., et al. (2025) · JMIR Formative Research · doi:10.2196/67047 · Cited by 3
Metadata
- Authors
- Wong, T. Y., & Sabanayagam, C.
- Venue
- Ophthalmologica
- Publisher
- S. Karger AG
- Published
- 2019-08-13
- Volume
- 243
- Issue
- 1
- Pages
- 9-20
- ISSN
- 0030-3755 (ISSN-L)
- 1423-0267
- OpenAlex
- W2976645659
- Cited by
- 310
- References
- 53
- FWCI
- 26.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.